Trial · NCT04676724
Adverse events474
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 474
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Agranulocytosis | Blood and lymphatic system disorders | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 0 | 55 | 0 |
| other | Agranulocytosis | Blood and lymphatic system disorders | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 1 | 53 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 3 | 55 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 1 | 53 | 3 |
| other | Coagulopathy | Blood and lymphatic system disorders | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 0 | 55 | 0 |
| other | Coagulopathy | Blood and lymphatic system disorders | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 1 | 53 | 1 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 1 | 55 | 1 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 0 | 53 | 0 |
| other | Leukopenia | Blood and lymphatic system disorders | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 10 | 55 | 18 |
| other | Leukopenia | Blood and lymphatic system disorders | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 7 | 53 | 10 |
| other | Neutropenia | Blood and lymphatic system disorders | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 10 | 55 | 25 |
| other | Neutropenia | Blood and lymphatic system disorders | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 12 | 53 | 21 |
| other | Neutrophilia | Blood and lymphatic system disorders | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 1 | 55 | 1 |
| other | Neutrophilia | Blood and lymphatic system disorders | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 0 | 53 | 0 |
| other | Pancytopenia | Blood and lymphatic system disorders | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 1 | 55 | 1 |
| other | Pancytopenia | Blood and lymphatic system disorders | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 0 | 53 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 14 | 55 | 20 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 11 | 53 | 16 |
| other | Bundle branch block left | Cardiac disorders | GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks) | 0 | 55 | 0 |
| other | Bundle branch block left | Cardiac disorders | GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks) | 1 | 53 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04676724/events